Ramona Rath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ramona Rath has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Hecker
Department of General, Visceral, Thoracic and Transplant Surgery, University Hospital Giessen, Justus-Liebig-University Giessen, Rudolf-Buchheim-Strasse 6, 35392 Giessen, Germany
1 shared publication - Christian Koch
Department of Anesthesiology, Operative Intensive Care Medicine and Pain Therapy, University Hospital of Giessen and Marburg, Rudolf-Buchheim-Strasse 7, 35392 Giessen, Germany
1 shared publication - Emmanuel Schneck
Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie, Universitätsklinikum Gießen und Marburg (UKGM), Justus-Liebig-Universität Gießen, Gießen, Deutschland
1 shared publication - Ingolf Askevold
Department of General, Visceral, Thoracic and Transplant Surgery, University Hospital Giessen, Justus-Liebig-University Giessen, Rudolf-Buchheim-Strasse 6, 35392 Giessen, Germany
1 shared publication - Konstantin Mayer
Department of Pulmonology and Sleep Medicine ViDia Clinics Karlsruhe Germany
1 shared publication - Martin Reichert
Department of General, Visceral, Thoracic, and Transplant Surgery, Giessen University Hospital, Justus-Liebig-University of Giessen, Giessen, Germany
1 shared publication
Latest Publications
- Open Access
- 16 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4142
Chronic Lung Allograft Dysfunction Is Associated with Increased Levels of Cell-Free Mitochondrial DNA in Bronchoalveolar Lavage Fluid of Lung Transplant Recipients
Chronic Lung Allograft Dysfunction (CLAD) is a life-threatening complication that limits the long-term survival of lung transplantation patients. Early diagnosis remains the basis of efficient management of CLAD, making the need for distinctive biomarkers critical. This explorative study aimed to investigate the predictive power of mitochondrial DNA (mtDNA) derived from bronchoalveolar lavages (BAL) to detect CLAD. The study included 106 lung transplant recipients and analyzed 286 BAL samples for cell count, cell differentiation, and inflammatory and mitochondrial biomarkers, including mtDNA. A receiver operating curve analysis of mtDNA levels was used to assess its ability to detect CLAD. The results revealed a discriminatory pro-inflammatory cytokine profile in the BAL fluid of CLAD patients. The concentration of mtDNA increased in step with each CLAD stage, reaching its highest concentration in stage 4, and correlated significantly with decreasing FEV1. The receiver operating curve analysis of mtDNA in BAL revealed a moderate prediction of CLAD when all stages were grouped together (AUROC 0.75, p-value < 0.0001). This study has found the concentration mtDNA in BAL to be a potential predictor for the early detection of CLAD and the differentiation of different CLAD stages, independent of the underlying pathology.
- 16 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4142
Open AccessChronic Lung Allograft Dysfunction Is Associated with Increased Levels of Cell-Free Mitochondrial DNA in Bronchoalveolar Lavage Fluid of Lung Transplant Recipients
Chronic Lung Allograft Dysfunction (CLAD) is a life-threatening complication that limits the long-term survival of lung transplantation patients. Early diagnosis remains the basis of efficient management of CLAD, making the need for distinctive biomarkers critical. This explorative study aimed to investigate the predictive power of mitochondrial DNA (mtDNA) derived from bronchoalveolar lavages (BAL) to detect CLAD. The study included 106 lung transplant recipients and analyzed 286 BAL samples for cell count, cell differentiation, and inflammatory and mitochondrial biomarkers, including mtDNA. A receiver operating curve analysis of mtDNA levels was used to assess its ability to detect CLAD. The results revealed a discriminatory pro-inflammatory cytokine profile in the BAL fluid of CLAD patients. The concentration of mtDNA increased in step with each CLAD stage, reaching its highest concentration in stage 4, and correlated significantly with decreasing FEV1. The receiver operating curve analysis of mtDNA in BAL revealed a moderate prediction of CLAD when all stages were grouped together (AUROC 0.75, p-value < 0.0001). This study has found the concentration mtDNA in BAL to be a potential predictor for the early detection of CLAD and the differentiation of different CLAD stages, independent of the underlying pathology.